Compare Petróleo Brasileiro SA (PBR) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs 10X Genomics Inc — how do they compare? Petróleo Brasileiro SA trades at $20.76 (market cap $128.30B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Petróleo Brasileiro SA is far larger — about 15× 10X Genomics Inc's market cap, and Petróleo Brasileiro SA pays a 8.07% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| PBR | TXG | |
|---|---|---|
Market Cap | $128.30B | $8.55B |
Sector | Technology | Health |
52-Week High | $22.03 | $67.29 |
52-Week Low | $11.54 | $11.34 |
Enterprise Value | $188.72B | $8.08B |
Dividend Yield | 8.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBR trades at $20.83, up 3.53% today, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a low P/E of 5.26, robust net income margin of 24.52%, and record Q2 2026 earnings beating estimates. Recent news highlights regulatory approvals for new drilling in Brazil and exploration in Ghana, signaling growth potential.
Outlook is positive given low valuation, high profitability, and expansion efforts, but risks include geopolitical factors and oil price volatility. Analyst consensus leans bullish with 50% buy ratings, though the stock faces headwinds from softer crude prices and execution risks in new projects.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
